Key Points
- Insider Timothy Moran sold 3,192 shares for $94,355.52 at an average price of $29.56, reducing his stake by 4.81% to 63,153 shares. The sale covered tax withholding on vested equity awards.
- Kestra reported a quarterly loss of $0.75 per share, missing analysts’ $0.61 loss estimate, on revenue of $30.97 million; the stock was reported down 6.5%.
- Analysts’ consensus rating is Moderate Buy, with an average price target of $29. Institutional investors also recently increased or initiated positions in the company.
Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) insider Timothy Moran sold 3,192 shares of the business's stock in a transaction that occurred on Tuesday, November 3rd. The stock was sold at an average price of $29.56, for a total transaction of $94,355.52. Following the completion of the transaction, the insider owned 63,153 shares in the company, valued at $1,866,802.68. This trade represents a 4.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Kestra Medical Technologies Trading Down 6.5%
KMTS opened at $28.53 on Friday. Kestra Medical Technologies, Ltd. has a twelve month low of $17.34 and a twelve month high of $31.91. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.33. The company has a fifty day moving average of $26.90 and a 200-day moving average of $23.96. The stock has a market cap of $1.70 billion, a PE ratio of -10.69 and a beta of 0.45.
Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last announced its earnings results on Monday, September 14th. The company reported ($0.75) earnings per share for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.14). The firm had revenue of $30.97 million for the quarter. Kestra Medical Technologies had a negative return on equity of 63.83% and a negative net margin of 140.43%. On average, sell-side analysts predict that Kestra Medical Technologies, Ltd. will post -2.45 EPS for the current year.
Hedge Funds Weigh In On Kestra Medical Technologies
Institutional investors have recently made changes to their positions in the stock. Corient Private Wealth LP boosted its position in shares of Kestra Medical Technologies by 284.2% during the 2nd quarter. Corient Private Wealth LP now owns 60,614 shares of the company's stock worth $1,542,000 after purchasing an additional 44,839 shares in the last quarter. Sei Investments Co. grew its stake in shares of Kestra Medical Technologies by 22.6% in the 1st quarter. Sei Investments Co. now owns 237,116 shares of the company's stock valued at $4,726,000 after buying an additional 43,753 shares during the period. Spartan Wealth Advisory Services LLC bought a new stake in Kestra Medical Technologies in the 1st quarter valued at about $603,000. Bank of New York Mellon Corp increased its position in Kestra Medical Technologies by 47.2% in the 1st quarter. Bank of New York Mellon Corp now owns 70,113 shares of the company's stock valued at $1,397,000 after buying an additional 22,471 shares in the last quarter. Finally, Quantinno Capital Management LP acquired a new position in Kestra Medical Technologies during the 1st quarter worth approximately $431,000.
Wall Street Analyst Weigh In
KMTS has been the subject of several research analyst reports. BTIG Research reissued a "buy" rating and issued a $32.00 price objective on shares of Kestra Medical Technologies in a research report on Tuesday, September 15th. JPMorgan Chase & Co. assumed coverage on Kestra Medical Technologies in a research note on Monday, August 10th. They issued an "overweight" rating and a $30.00 price target on the stock. Piper Sandler restated an "overweight" rating on shares of Kestra Medical Technologies in a report on Tuesday, September 15th. Weiss Ratings raised shares of Kestra Medical Technologies from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Wednesday, September 16th. Finally, Evercore started coverage on shares of Kestra Medical Technologies in a research note on Tuesday, October 20th. They issued an "outperform" rating and a $34.00 price objective for the company. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $29.00.
View Our Latest Research Report on Kestra Medical Technologies
Kestra Medical Technologies Company Profile
(
Get Free Report)
Kestra Medical Technologies, Inc is a medical technology company focused on developing and commercializing wearable solutions for patients at risk of sudden cardiac arrest. Its primary product is the ASSURE wearable cardioverter defibrillator, a wearable device designed to continuously monitor a patient's heart rhythm and deliver a therapeutic shock when clinically necessary.
The company's platform combines cardiac monitoring, arrhythmia detection and defibrillation capabilities in a wearable system intended for use outside the hospital.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
